AV Darunavir
(Die Seite wurde neu angelegt: „{{up|PHA antivirals by mechanism}} ---- drug: darunavir comb: cobicistat ---- {{tp|p=32671131|t=2020. Antiviral Activity and Safety of Darunavir/Cobicistat for…“) |
K |
||
| (Eine dazwischenliegende Version von einem Benutzer wird nicht angezeigt) | |||
| Zeile 4: | Zeile 4: | ||
comb: cobicistat | comb: cobicistat | ||
---- | ---- | ||
| + | {{tp|p=32325127|t=2020. Darunavir does not prevent SARS-CoV-2 infection in HIV patients |pdf=|usr=}} | ||
| + | {{tp|p=32479865|t=2020. Lack of antiviral activity of darunavir against SARS-CoV-2.|pdf=|usr=008}} | ||
{{tp|p=32671131|t=2020. Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19.|pdf=|usr=014}} | {{tp|p=32671131|t=2020. Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19.|pdf=|usr=014}} | ||
{{tp|p=32676695|t=2020. Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.|pdf=|usr=014}} | {{tp|p=32676695|t=2020. Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.|pdf=|usr=014}} | ||
| Zeile 10: | Zeile 12: | ||
{{tp|p=33221868|t=2020. Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.|pdf=|usr=021}} | {{tp|p=33221868|t=2020. Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.|pdf=|usr=021}} | ||
{{tp|p=C7337805|t=?. Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19.|pdf=|usr=015}} | {{tp|p=C7337805|t=?. Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19.|pdf=|usr=015}} | ||
| + | {{tp|p=32292805|t=2020. Data on the stability of darunavir/cobicistat suspension after tablet manipulation.|pdf=|usr=011}} | ||
| + | {{tp|p=31676833|t=2019. The HIV protease inhibitor darunavir prevents kidney injury via HIV-independent mechanisms.|pdf=|usr=}} | ||
| + | {{tp|p=32855991|t=2020. Reply to: "Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19".|pdf=|usr=018}} | ||
| + | {{ttp|p=32297571|t=2020. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus|pdf=|usr=}} | ||
Aktuelle Version vom 11. April 2021, 09:24 Uhr
| PHA antivirals by mechanism |
drug: darunavir comb: cobicistat
32325127 2020. Darunavir does not prevent SARS-CoV-2 infection in HIV patients
32479865 2020. Lack of antiviral activity of darunavir against SARS-CoV-2.
32671131 2020. Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19.
32676695 2020. Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.
32856282 2020. Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6.
32882767 2020. Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection.
33221868 2020. Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.
C7337805 ?. Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19.
32292805 2020. Data on the stability of darunavir/cobicistat suspension after tablet manipulation.
31676833 2019. The HIV protease inhibitor darunavir prevents kidney injury via HIV-independent mechanisms.
32855991 2020. Reply to: "Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19".
| 32297571 2020. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus |
